Drug Trial Radar · NCT06010173
Evaluation of Gadopiclenol for Magnetic Resonance Imaging (MRI) in Japanese Adults and Children
Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
240
Actual
Start
Jul 21, 2023
Primary completion
May 6, 2025
Study completion May 6, 2025
Sponsor
- Lead sponsor
- GuerbetIndustry
- Sponsor type
- Industry
- Collaborators
- Bracco Imaging S.p.A.
- First posted
- Aug 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
GDX-44-014 - GDX-101 study was conducted in Japan including 2 cohorts (adult cohort for adult population and pediatric cohort for pediatric population), with different designs: * The adult cohort had a prospective, multi-center, randomized, double-blind, controlled, and cross-over design. * The pediatric cohort had a prospective, multi-center, non-randomized, open-label and single arm design. The primary objective was to demonstrate the non-inferiority of gadopiclenol-enhanced MRI at 0.05 mmol/kg body weight (BW) compared to gadobutrol-enhanced MRI at 0.1 mmol/kg BW in terms of lesion visualization for adult patients referred for contrast-enhanced MRI of Central Nervous System (CNS) or Body regions.
Conditions
- Lesion in Body Region
- CNS Lesion
Interventions
GadopiclenolDrug
Dose/volume: Gadopiclenol administered was calculated based on patient's weight at the dose of 0.05 mmol/kg BW
Comparator (gadobutrol)Drug
Dose/volume of comparator: Gadobutrol administered was calculated based on patient's weight at the dose of 0.1 mmol/kg BW.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Lesion Visualization on Paired Images: Border DelineationTime frame: At each MRI exam: the first MRI at Day 1 and the second MRI performed after a wash out period of 2 to 14 days (adult cohort)
- Lesion Visualization on Paired Images: Internal MorphologyTime frame: At each MRI exam: the first MRI at Day 1 and the second MRI performed after a wash out period of 2 to 14 days (adult cohort)
- Lesion Visualization on Paired Images: Degree of Contrast EnhancementTime frame: At each MRI exam: the first MRI at Day 1 and the second MRI performed after a wash out period of 2 to 14 days (adult cohort)
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
Meitetsu Hospital
Aichi, Japan
Fukuoka University Hospital
Fukuoka, Japan
Gifu University Hospital
Gifu, Japan
Gunma University Hospital
Gunma, Japan
Hiroshima City Hiroshima Citizens Hospital
Hiroshima, Japan
Nakamura Memorial Hospital
Hokkaido, Japan
National Hospital Organization Shikoku Medical Center for Children and Adults
Kagawa, Japan
Kanagawa Children's Medical Center
Kanagawa, Japan
Kobe City Medical Center General Hospital
Kobe, Japan
University Hospital, Kyoto Prefectural University of Medicine
Kyoto, Japan
Kyoto City Hospital
Kyoto, Japan
Tohoku University Hospital
Miyagi, Japan
Nara Medical University Hospital
Nara, Japan
Kawasaki Medical School Hospital
Okayama, Japan
Osaka Metropolitan University Hospital
Osaka, Japan
Tominaga Hospital
Osaka, Japan
Saitama Prefectural Children's Medical Center
Saitama, Japan
Shin-Kuki General Hospital
Saitama, Japan
Shizuoka General Hospital
Shizuoka, Japan
Hamamatsu University Hospital
Shizuoka, Japan
Jichi Medical University Hospital
Tochigi, Japan
Tokyo Shinagawa Hospital
Tokyo, Japan
Toho University Omori Medical Center
Tokyo, Japan
National Center for Child Health and Development
Tokyo, Japan
Tokyo Metropolitan Children's Medical Center
Tokyo, Japan
Kurobe City Hospital
Toyama, Japan
Yamaguchi University Hospital
Yamaguchi, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.